Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
$6.83
+2.2%
$7.02
$4.07
$19.19
$422.44M1.63855,625 shs1.44 million shs
Geron Co. stock logo
GERN
Geron
$3.58
+2.3%
$2.80
$1.64
$4.05
$1.91B0.629.96 million shs6.62 million shs
Lannett Company, Inc. stock logo
LCI
Lannett
$1.54
$0.64
$3.72
$7.38M0.9592,067 shs280,600 shs
Organigram Holdings Inc. stock logo
OGI
Organigram
$1.93
-1.0%
$2.09
$0.97
$2.91
$201.25M1.092.27 million shs775,826 shs
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$6.79
-0.9%
$5.76
$2.86
$7.76
$290.58M1.88169,346 shs114,880 shs
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
+2.25%+1.79%0.00%-1.30%-63.22%
Geron Co. stock logo
GERN
Geron
+2.29%-2.72%+9.82%+65.74%+47.93%
Lannett Company, Inc. stock logo
LCI
Lannett
0.00%0.00%0.00%0.00%0.00%
Organigram Holdings Inc. stock logo
OGI
Organigram
-1.03%+5.46%-23.41%+19.14%-5.15%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-0.88%-3.82%+34.19%+19.96%+9.52%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
3.8803 of 5 stars
3.43.00.04.52.71.70.0
Geron Co. stock logo
GERN
Geron
3.2734 of 5 stars
3.53.00.01.31.41.70.6
Lannett Company, Inc. stock logo
LCI
Lannett
N/AN/AN/AN/AN/AN/AN/AN/A
Organigram Holdings Inc. stock logo
OGI
Organigram
N/AN/AN/AN/AN/AN/AN/AN/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
3.5795 of 5 stars
3.51.00.04.70.62.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
2.75
Moderate Buy$14.25108.64% Upside
Geron Co. stock logo
GERN
Geron
3.00
Buy$5.3348.98% Upside
Lannett Company, Inc. stock logo
LCI
Lannett
N/AN/AN/AN/A
Organigram Holdings Inc. stock logo
OGI
Organigram
3.00
BuyN/AN/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
3.00
Buy$11.2565.68% Upside

Current Analyst Ratings

Latest VRCA, CDMO, GERN, OGI, and LCI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/15/2024
Organigram Holdings Inc. stock logo
OGI
Organigram
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy
4/11/2024
Geron Co. stock logo
GERN
Geron
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
4/10/2024
Geron Co. stock logo
GERN
Geron
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$6.00
4/10/2024
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
3/15/2024
Geron Co. stock logo
GERN
Geron
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$6.00
3/15/2024
Geron Co. stock logo
GERN
Geron
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$4.00 ➝ $5.00
3/15/2024
Geron Co. stock logo
GERN
Geron
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$4.00 ➝ $5.00
3/7/2024
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$7.00
3/1/2024
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $13.00
3/1/2024
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
2/28/2024
Geron Co. stock logo
GERN
Geron
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
$149.27M2.89$0.16 per share43.31$3.03 per share2.25
Geron Co. stock logo
GERN
Geron
$240K8,157.48N/AN/A$0.46 per share7.78
Lannett Company, Inc. stock logo
LCI
Lannett
$340.58M0.00N/AN/A($23.34) per share0.00
Organigram Holdings Inc. stock logo
OGI
Organigram
$120.01M1.66N/AN/A$2.48 per share0.78
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$5.12M56.26N/AN/A$0.47 per share14.45

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
$560K-$0.17N/AN/A-8.12%-5.18%-2.16%4/29/2024 (Estimated)
Geron Co. stock logo
GERN
Geron
-$184.13M-$0.33N/AN/AN/A-77,691.14%-63.33%-44.71%5/9/2024 (Estimated)
Lannett Company, Inc. stock logo
LCI
Lannett
-$231.62M-$18.88N/AN/AN/A-62.40%N/A-13.39%N/A
Organigram Holdings Inc. stock logo
OGI
Organigram
-$184.34M-$0.80N/AN/AN/A-173.48%-30.94%-27.70%4/30/2024 (Estimated)
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$67M-$1.46N/AN/AN/A-1,307.47%-119.46%-70.35%5/14/2024 (Estimated)

Latest VRCA, CDMO, GERN, OGI, and LCI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/29/2024Q4 2023
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$0.47-$0.48-$0.01-$0.43$1.10 million$1.99 million    
2/28/2024Q4 23
Geron Co. stock logo
GERN
Geron
-$0.10-$0.09+$0.01-$0.09$0.06 million$0.02 million    
2/13/2024Q1 2024
Organigram Holdings Inc. stock logo
OGI
Organigram
-$0.10-$0.14-$0.04-$0.14$28.61 million$26.78 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
N/AN/AN/AN/AN/A
Geron Co. stock logo
GERN
Geron
N/AN/AN/AN/AN/A
Lannett Company, Inc. stock logo
LCI
Lannett
N/AN/AN/AN/AN/A
Organigram Holdings Inc. stock logo
OGI
Organigram
N/AN/AN/AN/AN/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
0.81
1.35
0.85
Geron Co. stock logo
GERN
Geron
0.14
3.16
3.16
Lannett Company, Inc. stock logo
LCI
Lannett
N/A
2.23
1.39
Organigram Holdings Inc. stock logo
OGI
Organigram
N/A
4.28
2.11
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
2.22
4.55
4.49

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
97.16%
Geron Co. stock logo
GERN
Geron
73.71%
Lannett Company, Inc. stock logo
LCI
Lannett
40.28%
Organigram Holdings Inc. stock logo
OGI
Organigram
34.63%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
42.45%

Insider Ownership

CompanyInsider Ownership
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
2.39%
Geron Co. stock logo
GERN
Geron
3.10%
Lannett Company, Inc. stock logo
LCI
Lannett
13.12%
Organigram Holdings Inc. stock logo
OGI
Organigram
0.09%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
41.50%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
36563.24 million61.73 millionOptionable
Geron Co. stock logo
GERN
Geron
141546.87 million529.92 millionOptionable
Lannett Company, Inc. stock logo
LCI
Lannett
81010.77 million9.35 millionOptionable
Organigram Holdings Inc. stock logo
OGI
Organigram
984103.20 million103.11 millionOptionable
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
10042.42 million24.82 millionOptionable

VRCA, CDMO, GERN, OGI, and LCI Headlines

SourceHeadline
Verrica Pharmaceuticals Inc (VRCA)Verrica Pharmaceuticals Inc (VRCA)
investing.com - April 19 at 7:13 PM
Needham & Company LLC Reiterates "Buy" Rating for Verrica Pharmaceuticals (NASDAQ:VRCA)Needham & Company LLC Reiterates "Buy" Rating for Verrica Pharmaceuticals (NASDAQ:VRCA)
marketbeat.com - April 10 at 8:24 AM
Verrica Pharmaceuticals to Spotlight Innovations at Needham Healthcare ConferenceVerrica Pharmaceuticals to Spotlight Innovations at Needham Healthcare Conference
msn.com - April 4 at 11:15 AM
Strong week for Verrica Pharmaceuticals (NASDAQ:VRCA) shareholders doesnt alleviate pain of three-year lossStrong week for Verrica Pharmaceuticals (NASDAQ:VRCA) shareholders doesn't alleviate pain of three-year loss
finance.yahoo.com - April 3 at 8:23 AM
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare ConferenceVerrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
globenewswire.com - April 2 at 7:30 AM
Verrica Pharmaceuticals Secures Key FDA Designation for YCANTH, Enhancing Market ProtectionVerrica Pharmaceuticals Secures Key FDA Designation for YCANTH, Enhancing Market Protection
msn.com - March 31 at 11:37 AM
Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDAVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDA
finanznachrichten.de - March 28 at 3:45 PM
Verrica Pharma gains as FDA lists Ycanth in Orange BookVerrica Pharma gains as FDA lists Ycanth in Orange Book
msn.com - March 27 at 3:42 AM
Verrica Pharmaceuticals: YCANTH Granted NCE Status By FDA - Quick FactsVerrica Pharmaceuticals: YCANTH Granted NCE Status By FDA - Quick Facts
markets.businessinsider.com - March 26 at 8:15 AM
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDAVerrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
globenewswire.com - March 26 at 7:30 AM
Verrica Pharmaceuticals Set to Illuminate TD Cowen Healthcare Conference with Fireside ChatVerrica Pharmaceuticals Set to Illuminate TD Cowen Healthcare Conference with Fireside Chat
msn.com - March 3 at 10:22 PM
Verrica Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS In LineVerrica Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
finance.yahoo.com - March 2 at 10:39 AM
When Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Become Profitable?When Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Become Profitable?
finance.yahoo.com - March 2 at 10:39 AM
Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial ResultsVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
finanznachrichten.de - March 1 at 11:46 PM
Verrica Pharmaceuticals Outperforms with YCANTH Sales, Promising Outlook Spurs Buy RatingVerrica Pharmaceuticals Outperforms with YCANTH Sales, Promising Outlook Spurs Buy Rating
markets.businessinsider.com - March 1 at 6:46 PM
Buy Rating Affirmed for Verrica Pharmaceuticals Following Strong Ycanth Launch and Strategic Market ExpansionBuy Rating Affirmed for Verrica Pharmaceuticals Following Strong Ycanth Launch and Strategic Market Expansion
markets.businessinsider.com - March 1 at 6:46 PM
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call TranscriptVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 1 at 1:45 PM
Buy Rating Affirmed for Verrica Pharmaceuticals Amidst Promising Ycanth Launch and Market AcceptanceBuy Rating Affirmed for Verrica Pharmaceuticals Amidst Promising Ycanth Launch and Market Acceptance
markets.businessinsider.com - February 29 at 10:09 PM
Verrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial ResultsVerrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial Results
finance.yahoo.com - February 29 at 12:07 PM
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial ResultsVerrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
globenewswire.com - February 29 at 7:30 AM
Earnings Outlook For Verrica PharmaceuticalsEarnings Outlook For Verrica Pharmaceuticals
benzinga.com - February 28 at 6:01 PM
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare ConferenceVerrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
globenewswire.com - February 27 at 7:30 AM
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
finance.yahoo.com - February 22 at 10:58 AM
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
globenewswire.com - February 22 at 7:30 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Avid Bioservices logo

Avid Bioservices

NASDAQ:CDMO
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services of biologics for the biotechnology and biopharmaceutical industries. The company offers various services, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
Geron logo

Geron

NASDAQ:GERN
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Lannett logo

Lannett

NYSE:LCI
Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.
Organigram logo

Organigram

NASDAQ:OGI
Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.
Verrica Pharmaceuticals logo

Verrica Pharmaceuticals

NASDAQ:VRCA
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.